(
449
Results
)
Filter
Only match titles
What are you looking for?
-
Category
-
Type
-
Year
-
Keywords
-
Author
Apply filters
Knowledge Hub
Collapse
-
Advances in allergen immunotherapy I
-
Allergen immunotherapy has a role in the era of biologics (Con&Pro Session: Con)
-
Basophil activation test results change in birch pollen sensitized patients during first season of immunotherapy
-
Basophil sensitivity during immunotherapy in grass pollen-allergic patients
-
Component Resolved Diagnosis and pollen Immunotherapy indication
-
Contraindications to venom immunotherapy and risk factors for adverse events: any left?
-
Cutting edge allergen immunotherapy
-
Exposome modulation and immunotherapy in infants at higher risk of respiratory allergies
-
Flash Talks on allergen immunotherapy
-
Flash talks on allergen Immunotherapy I
-
Flash talks on food allergy and immunotherapy
-
How to improve compliance of allergen immunotherapy in the clinic?
-
Immunotherapy in severe asthma (AIT)
-
Immunotherapy to food allergy
-
Improving patient care with allergen immunotherapy (AIT): Lessons learned from randomised control trials (RCT) and real world evidence (RWE) studies
-
Is specific immunotherapy useful in atopic dermatitis?
-
New Perspectives on Allergen Immunotherapy
-
New Perspectives on Allergen Immunotherapy
-
Oral immunotherapy in Food Allergy. What is the consensus?
-
Prescribing immunotherapy to pollens in children: influence of geographical and sociological diversity
-
Safety and prediction of allergen immunotherapy
-
Standardisation of Allergen Immunotherapy products and Legal Considerations
-
Sustained unresponsiveness to tree nuts after low dose oral immunotherapy in children aged 9-24 months
-
Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy
Show more Event Resources (22)Show Less-
-
Allergen immunotherapy for respiratory allergy: quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool
-
Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs
-
COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals – EAACI recommendations
-
Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy
-
Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force
-
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
-
Placebo effects in allergen immunotherapy – An EAACI Task Force Position Paper
-
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper
-
The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project
-
Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies – Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology task force
Show more Position Papers (8)Show Less-
-
Aeroallergen immunotherapy before five years of age and elderly
-
Allergen Immunotherapy and Biologicals
-
Allergen immunotherapy and co-evaluation of COVID-19 vaccines
-
Eosinophilic esophagitis and allergen immunotherapy
-
Health economics of allergen immunotherapy
-
Nocebo effect of allergen immunotherapy
Show more Task Forces (4)Show Less-
-
“Allergen Harmony”: New data for a tailored and sustained food and respiratory immunotherapy effect
-
Allergen immunotherapy with allergoid-mannan conjugates: from basic science to clinical research
-
Best in both worlds – Demonstrating long-term effectiveness of allergy immunotherapy in the real world
-
Patients’ perspective : a must have for the future of Allergen Immunotherapy
-
Raising paediatric awareness through growing evidence for allergy immunotherapy – optimise the treatment of children suffering from respiratory allergy
-
Setting a new standard for grass subcutaneous immunotherapy
Show more Sponsored Symposia (4)Show Less-
Website
Collapse
-
2-year outcome of low-dose oral immunotherapy for children with severe cashew allergy
-
300 IR 5-grass pollen sublingual immunotherapy tablet for allergic rhinoconjunctivitis: A systematic review and meta-analysis of randomised studies
-
5-year patient-reported outcomes after oral immunotherapy using heat-modified peanuts: results from the BOPI (Boiled Peanut Oral Immunotherapy) study
-
5-year patient-reported outcomes after oral immunotherapy using heat-modified peanuts: results from the BOPI (Boiled Peanut Oral Immunotherapy) study
-
A comparison of conventional vs cluster updosing venom immunotherapy in children in a tertiary hospital
-
A delivery platform for food allergy immunotherapy based on dissolvable microneedle array patches with ovalbumin mesoporous silica nanoparticles
-
A dose ranging study of sting challenge and specific lgE, IgG4, venom skin test and basophil activation responses to ant venom immunotherapy with and without delta-inulin adjuvant
-
AI as a game-changer: predicting biomarkers to transform allergy immunotherapy
-
Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI trial): baseline peanut-specific T cell responses of participants
-
Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI trial): baseline peanut-specific T cell responses of participants
-
Absence of alpha-tryptase isoforms is associated with less severe adverse events during peanut-oral immunotherapy
-
Achieving Remission with Peanut Sublingual Immunotherapy
-
Active immunotherapy with recombinant Bet v 1
-
Adherence to venom immunotherapy : a french monocentric retrospective study
-
Advances in Allergen Immunotherapy
-
Advances in Allergen Immunotherapy (AIT)
-
Advances in Immunotherapy
-
Advances in Oral Immunotherapy
-
Advances in epicutaneous immunotherapy for the management of patients with food allergy
-
Allergen Immunotherapy
-
Allergen Immunotherapy
-
Allergen Immunotherapy Improves Bronchial Epithelial Tolerance and Antiviral Responses in Patients with House Dust Mite Allergic Asthma
-
Allergen Immunotherapy Improves Bronchial Epithelial Tolerance and Antiviral Responses in Patients with House Dust Mite Allergic Asthma
-
Allergen Immunotherapy decreases biologicals use in allergic rhinitis with chronic rhinosinusitis with nasal polyps (CRSwNP)
-
Allergen Immunotherapy for the prevention of respiratory allergy
-
Allergen Immunotherapy in the Republic of Kazakhstan
-
Allergen immunotherapy
-
Allergen immunotherapy
-
Allergen immunotherapy (AIT) in pregnancy, focus on the use of carbamylated monomeric allergoid
-
Allergen immunotherapy 01
-
Allergen immunotherapy 02
-
Allergen immunotherapy 03
-
Allergen immunotherapy 04
-
Allergen immunotherapy 05
-
Allergen immunotherapy 1
-
Allergen immunotherapy 2
-
Allergen immunotherapy 3
-
Allergen immunotherapy 4
-
Allergen immunotherapy 5
-
Allergen immunotherapy 6
-
Allergen immunotherapy 7
-
Allergen immunotherapy and Anaphylaxis
-
Allergen immunotherapy and biologicals: when and how
-
Allergen immunotherapy for airway allergy
-
Allergen immunotherapy for allergic disease: Indications and contraindications
-
Allergen immunotherapy for allergic disease: Indications and contraindications
-
Allergen immunotherapy in childhood: setting up the therapeutic goals
-
Allergen immunotherapy in clinical studies
-
Allergen immunotherapy in food allergy, what’s new?
-
Allergen immunotherapy in patients with allergic rhinitis and asthma associated with reduced risk of severe COVID-19
-
Allergen immunotherapy – Basic and clinical perspective
-
Allergen specific IgE is a stronger predictor of remission following Peanut Oral Immunotherapy in children aged 1-10 years
-
Allergen-specific IgE-blocking antibodies in the course of allergen immunotherapy
-
Allergen-specific IgE/IgG4 ratio as biomarker of allergen immunotherapy efficacy in house dust mite-sensitized allergic rhinitis
-
Allergen-specific immunotherapy based on purified and modified Fel d 1 allergen from cat dander
-
Allergic, but still want them: A Mix Pet Dander Immunotherapy
-
AllergoOncology: Application of the basophil activation test (BAT) in pre-clinical testing and the first-in-class clinical trial of anti-cancer IgE immunotherapy
-
AllergoOncology: Application of the basophil activation test (BAT) in pre-clinical testing and the first-in-class clinical trial of anti-cancer IgE immunotherapy
-
AllergoOncology: The role of BAT in pre-clinical and clinical assessments of potential hypersensitivity to anti-cancer IgE immunotherapy
-
Allergy Therapeutics – Setting a new standard for grass subcutaneous immunotherapy
-
Alterations in B cell memory induced by house dust mite allergen immunotherapy
-
An interim analysis of a multi-center, oPEn label, Randomized study to investigate the saFEty of an optimal acCelerated scheme for immunoTherapy in adolescent and adult patients with moderate to severe AR with or without asthma in China. (PERFECT)
-
Analysis of epinephrine use during peanut (Arachis hypogaea) allergen powder-dnfp oral immunotherapy in individuals with peanut allergy aged 1 to 3 years
-
Analysis of immunological and cellular tolerance biomarkers during bee venom immunotherapy
-
Analyzing Factors Influencing Adherence to Classify Adherence Levels in Patients Treated with Allergen Immunotherapy
-
Antioxidant pine nut protein hydrolysate as a therapeutic oral immunotherapy agent in a murine model of pine nut allergy
-
Application of allergen standardization in allergen-specific immunotherapy (AIT)
-
Artificial intelligence and precision immunology: pioneering biomarker discovery in allergen immunotherapy
-
Artificial intelligence-based B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in Blomia tropicalis
-
Assessing the role of specific IgA in prophylactic sublingual immunotherapy for peanut allergy: A Brown Norway rat study
-
Assessment of the Efficacy of Specific Immunotherapy After a Long Break in Asthmatic Patients
-
Asthma phenotype markers did not affect allergen immunotherapy effectiveness
-
Audit of Peanut Allergy Patients Eligible for Oral Immunotherapy (OIT) in a Paediatric Cohort at Galway University Hospital (2020-2023)
-
B Cell Repertoires and Phenotypes in Food Allergy and Oral Immunotherapy
-
BDNF as a biomarker for evaluating clinical response in allergic rhinitis patients undergoing allergen-specific immunotherapy
-
Basophil activation test as a predicting tool for effective Pru p 3 sublingual immunotherapy response in lipid transfer protein allergy
-
Best candidate for allergen-specific immunotherapy
-
Biologicals as adds on in oral immunotherapy for IgE mediated food allergy
-
Blocking antibodies from food immunotherapy unravelled at the molecular level
-
Build-Up of Wasp Venom Immunotherapy with Alutard-Depot SQ during Supply Shortage: A Retrospective Case Series
-
Bumblebee venom allergy as an emerging occupational allergy: safety and efficacy of bumblebee venom immunotherapy in a large single-center cohort
-
Carry-over effect of 300 IR house dust mite sublingual immunotherapy tablet and relationship with disease activity: a post hoc analysis
-
Challenges in food allergen immunotherapy
-
Changes in IgG4 and IgE epitope binding profile are greater with sublingual than oral immunotherapy in milk-allergic children, and correspond to efficacy outcomes
-
Changing Allergen Immunotherapy Practice Profiles in Mexico
-
Clinical Assessment of Specific Immunotherapy Efficacy in Individuals with House Dust Mite-Induced Allergic Rhinoconjunctivitis
-
Clinical Characteristics of Anaphylaxis Secondary to Subcutaneous Allergen-Specific Immunotherapy in a Pediatric Hospital in Mexico
-
Clinical Evaluation of subcutaneous immunotherapy (SCIT) containing a mixture of mites, in depot polymerized formulation without dilutional effect. Results from a prospective multicenter study
-
Clinical and immunological aspects in allergen immunotherapy
-
Clinical and immunological comparison between two subcutaneous immunotherapy products in children with allergic rhinitis
-
Clinical evaluation of an immunotherapy treatment with Vespa velutina venom in allergic patients. Results from a prospective multicenter Study: W-STING Study
-
Clinical outcomes used in allergen immunotherapy in allergic asthma in the era of Data Science
-
Clinical remission of allergic rhinoconjunctivitis with a 300IR 5-grass pollen sublingual immunotherapy tablet
-
Clinical studies on Allergen Immunotherapy with inhaled allergens: optimization and standardization of methodological approaches
-
Clinical studies on allergen immunotherapy with inhaled allergens: optimization and standardization of methodological approaches
-
Clonal mast cell disorders, allergy to hymenoptera venom and venom immunotherapy – our experience
-
Cluster immunotherapy for bee venom in delayed levo-tyrosine formulation with short protocol
-
Comparison of basophil activation by different yellow jacket venoms from three continents and venom used in immunotherapy
-
Comparison of the efficacy of subcutaneous and sublingual immunotherapy for the treatment of allergic asthma in children
-
Consistent long term benefit of allergen immunotherapy in patients with allergic rhinitis
-
Coordinated specific IgG2 and IgE responses are associated with high clinical benefit of allergen immunotherapy with 300 IR house dust mite sublingual tablets in a large European cohort
-
Cracking the Code: Immunological Changes Leading to Raw Egg Tolerance During Immunotherapy with Cooked Egg
-
Criteria used by health professionals on the selection of allergen immunotherapy in real clinical practice. CHOICE project results from Interim analysis 2023: PATIENT’S RESULTS
-
Criteria used by health professionals on the selection of allergen immunotherapy in real clinical practice. CHOICE project results from Interim analysis 2023: DOCTOR’S RESULTS
-
Cross-tolerance to cashew by prophylactic sublingual immunotherapy with different tree nuts in Brown Norway rats
-
Current knowledge on venom allergen immunotherapy
-
DBV Technologies – Epicutaneous route: an innovative potential approach to food immunotherapy
-
DRAGO Application: Implementing Adherence and to House Dust Mite Allergen Immunotherapy
-
Decreased frequency and severity of oral immunotherapy induced gastrointestinal eosinophilic reactions following revisions in treatment protocol
-
Delving deeper in allergen immunotherapy
-
Demystifying the fear of lack of adherence to sublingual immunotherapy (SLIT)
-
Descriptive Study on the Evolution of Patients Treated with Oral Immunotherapy (OIT) Using Pasteurized Egg White at the Fundación Alcorcón University Hospital
-
Descriptive study of the evolution of patients after oral immunotherapy with milk at the Hospital Universitario Fundación Alcorcón
-
Designing Modified Variants of Ara h 1 and Ara h 2 for Safe and Effective Immunotherapy
-
Development and implementation of an intelligence platform for management of allergen immunotherapy in China
-
Development of Eosinophilic Esophagitis in a Child with Multiple Food Allergies: The Role of Omalizumab, Oral Immunotherapy and Dietary Incompliance: A Case Report
-
Development of a thermosensitive poloxamer formulation designed to provide a controlled release of the active pharmaceutical ingredient in birch pollen allergen immunotherapy
-
Dietary outcomes following oral immunotherapy for cows milk allergy: Results from the SOCMA Study
-
Differential study of whole genome expression profiles of peripheral blood mononuclear cells in children with dust mite specific immunotherapy for asthma
-
Discovering new horizons in allergen immunotherapy
-
EFFECTIVENESS AND SAFETY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY WITH Pru p3 EXTRACT IN PATIENTS WITH LTP ALLERGY
-
Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients
-
Early immunotherapy with aeroallergens and impact on future allergy
-
Early inflammatory reactions in mice after immunotherapy with an allergen microcrystalline tyrosine adsorbate
-
Effect of 300 IR house dust mite sublingual immunotherapy tablet in paediatric patients and relationship with disease activity
-
Effect of Metformin on allergen specific immunotherapy
-
Effect of allergen – specific immunotherapy on PFS symptoms
-
Effect of allergen immunotherapy on quality of life
-
Effect of allergen specific immunotherapy on PFS symptoms
-
Effect of allergen specific immunotherapy on PFS symptoms
-
Effect of sublingual immunotherapy on allergic rhinitis: Real-life data analysis
-
Effectiveness and Safety Study of Subcutaneous Immunotherapy for Respiratory Allergy to Dermatophagoides and Lepidoglyphus Destructor
-
Effectiveness and safety of Venom ImmunoTherapy (VIT) with “Rapid Cluster” induction protocol
-
Effectiveness of House Dust Mite Subcutaneous Immunotherapy on Co-existing Allergen Symptoms in Polysensitized Patients with Allergic Rhinitis: A Multicenter Retrospective Analysis
-
Effectiveness of sublingual immunotherapy in patients with atopic dermatitis allergic to house dust mite: an open label extension study
-
Effectiveness of sublingual immunotherapy in patients with atopic dermatitis allergic to house dust mite: an open label extension study
-
Effectivity and serological correlation analysis in patients undergoing their first year of mixed subcutaneous immunotherapy for dust mites and cat
-
Efficacy Study on Intratonsillar Immunotherapy for Patients with Allergic Rhinitis Induced by House Dust Mites (Tonsil-AIT)
-
Efficacy and Safety of Hymenoptera Venom Immunotherapy
-
Efficacy and safety of HDM-specific subcutaneous immunotherapy on atopic dermatitis
-
Efficacy and safety of allergen immunotherapy in clinical practice
-
Efficacy and safety of sublingual immunotherapy for mite in children and adolescents with AR
-
Efficacy and safety profile of immunotherapy for multiple allergens in polysensitized patients with allergic rhinitis: a systematic review and meta-analysis
-
Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients with Diverse Sensitization Patterns: A Multicenter Study
-
Efficacy of virus-like particle (VLP)-based immunotherapy in a mouse model of HDM allergy
-
Epicutaneous Allergen Administration with Microneedles as a Novel Method of Immunotherapy for House Dust Mite (HDM) Allergic Rhinitis
-
Epicutaneous Immunotherapy : from mechanism to efficacy
-
Epicutaneous Immunotherapy with Peanut Allergy
-
Epicutaneous food allergen immunotherapy
-
Epitope Analysis and Mutation Design in Jug r 1 for Hypoallergenic Walnut Immunotherapy
-
Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study
-
Evaluation of auditory function in children with allergic rhinitis treated with specific immunotherapy
-
Evaluation of the IgEs amount and basophil activity changes during walnut oral immunotherapy
-
Evaluation of the efficacy, adverse effects, and cost-effectiveness of sublingual immunotherapy with dominant allergens for allergic rhinitis due to respiratory allergens in adults and children
-
Evaluation of the tolerability of the administration of subcutaneous immunotherapy in a cluster schedule, in patients with rhinoconjunctivitis and/or asthma with sensitization to Olea europaea with or without sensitization to grasses
-
Evaluation of total Immunoglobulin D in sublingual immunotherapy for allergic rhinitis
-
Evolution of pediatric patients with casein-specific IgE values>100 KU/L undergoing cow’s milk oral immunotherapy
-
Exacerbation of eosinophilic esophagitis in a child with seasonal allergic rhinitis during sublingual immunotherapy
-
Expansion of allergen-specific type 2 memory B cells with an altered phenotype after immunotherapy for bee venom or ryegrass pollen allergy
-
Experience with ALUTARD SQ Immunotherapy in Patients Allergic to Hymenoptera Venom
-
Exploring the Protective Potential: Subcutaneous Immunotherapy associated with C. acnes as a reductor of COVID-19 Severity in Older Patients – A Single-Center Observational Study
-
Exposure-adjusted safety of peanut (Arachis hypogaea) allergen powder-dnfp oral immunotherapy in individuals with peanut allergy aged 1-3 years (POSEIDON trial)
-
FRIENDLY TREE NUT AND SESAME ORAL IMMUNOTHERAPY PROTOCOTOLS (ALPEDIA-NOITs)
-
Factors associated with higher serum IgG4 response in children treated with allergen immunotherapy
-
Field Stings in Patients Undergoing Hymenoptera Venom Immunotherapy in a Healthcare Area of Central Spain
-
First clinical practice of using biologic therapy with dupilumab in combination with allergen-specific immunotherapy in a patient with severe atopic dermatitis and bronchial asthma
-
Fixed-Dose Oral Immunotherapy for High-Threshold Food Allergy: Efficacy and Safety in Real-World Practice
-
Flash talks on Allergen Immunotherapy 1
-
Flash talks on Allergen Immunotherapy 2
-
Flash talks on Allergen Immunotherapy 3
-
Flash talks on Allergen Immunotherapy 4
-
Flexible and Safe Oral Immunotherapy (OIT) Regimen Using Home Boiled Nut Broths (HBNB)
-
Food oral immunotherapy monitoring with OITcontrol® is related to reduced number of home adverse reactions and better treatment compliance compared with paper-based monitoring
-
Food oral immunotherapy monitoring with OITcontrol® is related to reduced number of home adverse reactions and better treatment compliance compared with paper-based monitoring
-
Food-allergen immunotherapy : how do I get started?
-
From allergen molecules to allergy management: can molecular diagnosis improve allergen immunotherapy efficacy?
-
Global Stage Session 3 – Successes and challenges of Immunotherapy
-
Gut Microbial Bile and Amino Acid Metabolism Associate with Peanut Oral Immunotherapy Failure
-
High degree of desensitization after one year of early-life peanut oral immunotherapy – SmaChO Randomized Controlled Trial
-
High degree of sustained unresponsiveness and safety after three years of slow up-dose peanut oral immunotherapy in toddlers – results from the SmaChO study (Small Children Oral Immunotherapy)
-
House dust mite sublingual immunotherapy comprehensively improves asthma and allergic rhinitis in children and adolescents
-
How allergists around the world perceive innovation in the context of allergen Immunotherapy AIT: an international survey
-
How effective and safe venom allergen immunotherapy is in children
-
Hymenoptera venom immunotherapy with 210 minutes Ultra-Rush protocol: patient profile and potential risk factors for systemic reactions
-
ILIT.NU: Intralymphatic immunotherapy and placebo affected cSMS similarly in grass pollen allergic individuals in a large clinical trial
-
ILIT.NU: Titration of Allergen for Treatment of Grass Pollen Induced Rhinoconjunctivitis with Intralymphatic Immunotherapy
-
Identification of the optimal immunotherapy via CAP Inhibition in Vespa velutina anaphylaxis patients
-
IgE High-Affinity Receptor Expression as a Predictive Biomarker for Oral Immunotherapy Outcomes in Severe Egg and Milk Allergies
-
IgG-Epitope Mapping of Birch-Pollen Bet v 1 Allergen in Allergic and Treated Patients for the Design of Hypoallergenic Immunotherapy Allergens
-
IgG-Epitope Mapping of Birch-Pollen Bet v 1 Allergen in Allergic and Treated Patients for the Design of Hypoallergenic Immunotherapy Allergens
-
Immune mechanisms of food immunotherapy
-
Immunologic profile and safety of milk oral immunotherapy in children with severe cow’s milk allergy – a series of cases
-
Immunophenotypes of Food Allergy and Responses to Immunotherapy Across the Life Course
-
Immunotherapy for LTP allergy
-
Immunotherapy for food allergy. What’s new?
-
Immunotherapy from patient and epidemiological study perspective
-
Immunotherapy in Food allergies : New frontiers
-
Immunotherapy in childhoood asthma: is it worth it?
-
Immunotherapy in food allergy
-
Immunotherapy in the clinic
-
Immunotherapy with Vespa velutina nigrithorax venom: safety of ultra-rush protocol and preliminary clinical results
-
Immunotherapy with Vespa velutina nigrithorax venom: safety of ultra-rush protocol and preliminary clinical results
-
Impact of Security Measures Implementation in Subcutaneous Allergen Immunotherapy Administration at a Pediatric Hospital in Mexico
-
Impact of a 3-tree sublingual immunotherapy liquid formulation in birch family pollen-allergic patients on prevention of disease progression and/or asthma onset
-
Impact of allergic rhinitis activity on the effect of 300IR house dust mite sublingual immunotherapy tablet in adolescent patients
-
Impact of different prophylactic sublingual immunotherapy regimes on peanut allergy prevention in Brown Norway rats
-
Impact of liquid sublingual immunotherapy on asthma worsening prevention: GINA treatment stepping up results from the real-world EfficAPSI study
-
Impact of liquid sublingual immunotherapy with mixed pollen allergens on asthma prevention in polyallergic patients: results from the real-world EfficAPSI study
-
Impact of participant baseline factors on exposure-adjusted incidence of treatment-related adverse events during peanut oral immunotherapy
-
Increase in maximum tolerated dose and decrease in symptom severity during food challenge in a clinical trial of oral immunotherapy for peanut allergy in children aged 1 to 3 years
-
Increased Inhibitory Surface Marker PD-1 Expression in CD4+T Cells and Th2+T Cells in Allergen-specific Immunotherapy
-
Increased the serum Blomia tropicalis antibody levels in children with Dermatophagoides pteronyssinus immunotherapy
-
Indefinite immunotherapy with different extracts in systemic mastocytosis
-
Individual Differences in Response to Dust-Mite-Allergen Specific Immunotherapy in Allergic Rhinitis: A Meta-analysis of Randomized Controlled Trials
-
Innovations in Food Allergy Immunotherapy
-
Interim safety review of PVX108 peptide immunotherapy in an ongoing Phase 2 trial in peanut-allergic adolescents and children
-
Intralymphatic immunotherapy of allergic rhinoconjunctivitis with grass allergoid microcrystalline tyrosine adsorbate produced reduced medication use and symptoms: a double-blind placebo-controlled trial
-
Intralymphatic immunotherapy with aluminium hydroxide based grass allergen reduced medication use in patients with allergic rhinoconjunctivitis: a double-blind randomized placebo-controlled trial
-
Intravenous immunotherapy with Der p 1-containing nanoparticles alleviates allergic response in a murine model of allergic rhinitis
-
Is milk oral immunotherapy using a home up-dosing protocol a viable and safe treatment for the older milk allergic child?
-
Kinetics of IgG4 after Vespula venom immunotherapy administered with an ultra-rush protocol
-
Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Reducing Infectious Events in Allergic Rhinitis Patients with and without Asthma
-
Long-term Follow-up After Peanut Oral Immunotherapy During Preschool Years: Lessons from the IMPACT Trial
-
Long-term efficacy and re-sting outcomes following venom immunotherapy discontinuation: A 978-patient analysis
-
Low dose oral immunotherapy for children with severe cow’s milk allergy
-
Machine Learning-Based Prediction of Desensitization Success in Oral Immunotherapy for Hen’s Egg Allergy in Children
-
Management of Eosinophilic Esophagitis as a side effect of food oral immunotherapy
-
Mapping the Patient’s Journey Prior to Allergen Immunotherapy
-
Microneedles-based transdermal allergen specific immunotherapy protects against gliadin induced anaphylaxis in a mouse model
-
Minimum resources to run an immunotherapy clinic safely
-
Missense variant KIT p.D816V suggestive of mast cell disorder predisposes to Hymenoptera venom immunotherapy treatment complications and failure
-
Missense variant KIT p.D816V suggestive of mast cell disorder predisposes to Hymenoptera venom immunotherapy treatment complications and failure
-
Modulation of B cell memory responses by house dust mite allergen immunotherapy
-
Modulation of allergen-specific type 2 memory B cells over the course of 18 months sublingual immunotherapy for house dust mite allergy
-
Molecular tools in support to walnut oral immunotherapy
-
Monitoring response to immunotherapy
-
Mucosal delivery of allergen-specific immunotherapy with vaccine adjuvants suppresses allergic disease through both humoral and cellular immune mechanisms
-
Murine IgG1 corresponding to human IgG4 increased by subcutaneous immunotherapy suppressed activation of group 2 innate lymphoid cells
-
Murine IgG1 increased by subcutaneous immunotherapy suppressed development of allergic asthma
-
NOVEL MULTI-NUTS ORAL IMMUNOTHERAPY PROTOCOLS (ALPEDIA-NOITs)
-
Nationwide pivotal registry study on house dust mite immunotherapy in allergic rhinitis patients with or without asthma in China (NAVIGATOR)
-
New directions in immunotherapy and vaccinology
-
New insights on allergen immunotherapy
-
New mechanisms for the induction of tolerance by Oral Immunotherapy
-
Novel allergen immunotherapy strategies
-
Nut immunotherapy – Is it ready for prime time?
-
One-strength dose escalation using a birch pollen allergoid for subcutaneous immunotherapy is safe and well-tolerated in children, adolescents and adults
-
One-year follow-up of children who achieved sustained unresponsiveness following early oral immunotherapy for various allergens
-
Oral Immunotherapy
-
Oral Immunotherapy for Adults with Food Allergies
-
Oral Immunotherapy for Fish Allergic Children
-
Oral Immunotherapy with omalizumab in an adult patient with severe milk and egg allergy
-
Oral immunotherapy (OIT) in walnut and hazelnut co-allergic patients: ELISA inhibition studies to direct treatment approach
-
Oral immunotherapy decreases expression of pro-inflammatory genes upon re-exposure to allergen in egg allergic children
-
Oral immunotherapy in cow’s milk allergic patients
-
Oral immunotherapy protocols for milk / egg
-
Oral immunotherapy protocols for milk / egg
-
Oral immunotherapy protocols for milk / egg
-
Oral immunotherapy to hazelnut in children: a single-center retrospective study in an Italian cohort
-
Outcomes of Bee Re-sting After Cessation of Venom Immunotherapy
-
Outcomes of low-dose peanut food challenges in preschoolers when initiating peanut oral immunotherapy
-
Ovalbumin-loaded nanoparticles for allergen specific immunotherapy
-
Passive immunotherapy with anti-Bet v 1 mAb
-
Patient preference: A multinational discrete-choice-experiment (DCE) in pollen allergen immunotherapy (AIT)
-
Patient-reported outcomes after 5 years of oral immunotherapy for peanut allergy: results from the BOPI (Boiled Peanut Oral Immunotherapy) study
-
Patients undergoing immunotherapy with Alternaria alternata: prevalence of asthma and co-sensitization to other allergens
-
Patterns of peanut ingestion in remission vs desensitized patients after completion of peanut oral immunotherapy at 3-years post-treatment
-
Peanut oral immunotherapy has not recuded basophil activation
-
Peanut oral immunotherapy in toddlers
-
Pediatric patients undergoing immunotherapy with alternaria alternata: demographic and clinical characterization
-
Persisten severe cow’s milk allergy with successful oral immunotherapy in adulthood
-
Poloxamer formulation for allergen immunotherapy reduces systemic allergic reactions in a mouse model
-
Positive effect of a 300IR dosing pump-administered liquid sublingual immunotherapy on allergic disease evolution: Results from the observational, prospective, longitudinal PRACTIS study
-
Positive impact on quality of life with a depigmented-polymerized house dust mite extract immunotherapy
-
Positive outcome of the pivotal Phase III study with PQ Grass, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system
-
Predicting clinical response to allergen-specific immunotherapy to D. pteronyssinus using serological pre-treatment parameters
-
Predicting the Efficacy of Allergen Immunotherapy in Asthma Based on Initial-Year Outcome: Insights from the Estimated Daily Symptom and Medication Score
-
Predicting treatment response to oral immunotherapy in peanut-allergic children using multi-omics risk scores
-
Predictors of response to oral immunotherapy
-
Prescription rates and adherence to bee- and vespid- immunotherapy in Austria – a population-based study
-
Present and future of allergen immunotherapy
-
Profile of patients treated with the 300IR liquid sublingual immunotherapy for cat allergy and perception of treatment effect: Results from a French survey
-
Prognostic value of specific IgE ratios in the tolerance of oral immunotherapy with egg allergy
-
Progress in understanding the mechanisms of airborne allergen immunotherapy
-
Prospective, pilot, phase 1 study of iPUMP© in patients starting sublingual allergen immunotherapy (Staloral©)
-
Protein and allergen content variability of peanut-containing products used in oral immunotherapy for peanut allergy
-
Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites
-
Protocols for venom immunotherapy in the era of depot formulations
-
Randomized Controlled Trial of Sublingual Immunotherapy for Egg Allergy
-
Randomized controlled trial of pancake oral immunotherapy for egg allergy
-
Reactions Due to Accidental Peanut Consumption During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers
-
Real-World Protective Effects of Epicutaneous Immunotherapy in Peanut-allergic Toddlers
-
Real-life Non-interventional Post authorization Safety Study with the SQ tree sublingual immunotherapy tablet
-
Real-life experience of allergen-specific immunotherapy
-
Real-life experience with long-term oral immunotherapy for nut allergic children: A single center study from Luxembourg
-
Real-life experience with long-term oral immunotherapy for nut allergic children: A single center study from Luxembourg
-
Real-world allergen immunotherapy effectiveness in allergic asthma
-
Risk Factors for Early Adverse Events of Sublingual Immunotherapy for Allergic Rhinitis and their Impact on Short-term Treatment Outcomes
-
Role of sublingual immunotherapy in management of patients with moderate to severe allergic rhinitis; one year study
-
SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet is well-tolerated in children with inadequately controlled HDM allergic asthma
-
Safety Data for House Dust Mite and Pollen Subcutaneous Allergen Immunotherapy in Children: Systemic Reactions and Risk Factors
-
Safety Profile and Clinical Outcome of Sublingual Immunotherapy (SLIT) with Pru p 3 in Patients with LTP Allergy Undergoing Food Reintroduction
-
Safety and Tolerability of Rush Updosing Using a Mugwort Allergoid Extract for Subcutaneous Allergen Immunotherapy
-
Safety and compliance of sublingual immunotherapy with house dust mite extract in patients with atopic dermatitis for 1 year
-
Safety and efficacy of a 7-week immunotherapy protocol with aluminum hydroxide adsorbed bee venom
-
Safety and tolerability of in-season initiation of subcutaneous and sublingual allergen immunotherapy with SQ grass pollen products: a comprehensive review
-
Safety and tolerance response of a two day rush protocol treatment in immunotherapy using purified Apis mellifera dry Honeybee venom extract
-
Safety of Hymenoptera Venom Immunotherapy in Patients with Oncological and Autoimmune Diseases: A Clinical Case Series
-
Safety of a cluster strategy, effectiveness and immunological changes in allergic children sensitized to house dust mites with native and modified subcutaneous immunotherapy treatment
-
Safety of oral immunotherapy in preschool aged children with single and multiple food allergy (the ORKA trial): a prospective intervention study
-
Safety of subcutaneous immunotherapy with mixtures of two allergens at maximum concentration: 10 year real-world data
-
Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix
-
Safety profile in clinical trials of sublingual immunotherapy with carbamylated monomeric allergoid
-
Selecting the right immunotherapy for Vespa velutina nigrithorax anaphylaxis: does one treatment fits all?
-
Short-term benefits of sublingual immunotherapy in routine clinical practice: Patient Benefit Index by class in the observational, prospective, longitudinal study PRACTIS
-
Short-term benefits of sublingual immunotherapy in routine clinical practice: deciphering factors influencing the patient satisfaction in the observational, prospective, longitudinal study PRACTIS
-
Should we be concerned when starting allergen immunotherapy in patients with controlled HIV infection or autoimmune diseases?
-
Slow oral immunotherapy for food allergy – what evidence do we have?
-
Small Doses, Big Benefits: The Promise of Low-Dose Oral Immunotherapy
-
Specific IgE and IgG4 changes in adults undergoing peanut immunotherapy combined with omalizumab
-
Stallergenes Greer – “Allergen Harmony”: New data for a tailored and sustained food and respiratory immunotherapy effect
-
Starting with Low-Dose Sesame Food Challenges for Oral Immunotherapy
-
Steroid sparing effect of 300IR house dust mite sublingual immunotherapy tablet in mite allergic rhinitis patients with concomitant asthma
-
Study design for A multicenter, open label, randomized Study to inveStigate the effIcacy of Subcutaneous immunoTherapy combined with vitamin D3 in children and adolescent patients with allergic rhinitis (ASSIST study)
-
Study design for efficacy evaluation of subcutaneOus immunotherApy in patients with obstructive Sleep apnea concomitant with allergIc rhinitiS (OASIS study)
-
Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)
-
Study of Efficacy of Rush Sub Lingual Immunotherapy (RSLIT) in Cases of Severe Persistent Allergic Rhinitis
-
Subcutaneous Allergen-specific Immunotherapy in Pediatric Age – a level II hospital experience
-
Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions
-
Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions
-
Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is safe in a pre/co-seasonal treatment regimen – a subgroup comparison
-
Sublingual allergen immunotherapy in children with AR
-
Sublingual dust mite allergen immunotherapy reduces respiratory infections in children with allergic rhinitis
-
Sublingual immunotherapy for house dust mite allergy induces expansions of allergen-specific memory B cells expressing CD29 and downregulating IL4Rα
-
Sublingual immunotherapy with Pru p 3 induces DNA methylation changes towards tolerance in dendritic cells from patients with nsLTP allergy
-
Sublingual immunotherapy with peanut protein extract has an effect in Brown Norway rats sensitised via the skin
-
Successes and challenges of Immunotherapy
-
Successes and challenges of Immunotherapy
-
Successes and challenges of Immunotherapy
-
Successes and challenges of Immunotherapy in Poland and EU
-
Successful immunotherapy with cow’s milk and omalizumab in a 24-year-old patient with extreme cow’s milk allergy
-
Sustained and Long-term effect of allergen immunotherapy in local respiratory allergy
-
Sympout study: Evolution of clinical parameters in a pediatric population allergic to pollens or house dust mites treated with sublingual immunotherapy in liquid formulation standardized in TBU/ml
-
Sympout study: Need of medication for symptom control in patients with rhinitis and/or bronchial asthma due to house dust mites or pollens in treatment with sublingual immunotherapy in a standardized liquid formulation in TBU/ml
-
Systematic literature review and adjusted indirect treatment comparisons of 2 allergen immunotherapy treatments for grass pollen–induced allergic rhinitis
-
Systemic allergic reactions to subcutaneous allergen immunotherapy – A single center experience
-
Systemic reactions to subcutaneous immunotherapy in children
-
TAPAS – a long-term non-interventional study evaluating MCT (MicroCrystalline Tyrosine)-associated allergoids shows non-inferiority of clinical effectiveness in children compared to adults during a 3-year course of allergen immunotherapy
-
The Efficacy of Sublingual Immunotherapy in Mild versus Moderate Atopic Dermatitis Among Children with House Dust Mite Allergic Rhinitis
-
The Quest for Tolerance in Allergen Immunotherapy
-
The Sting Challenge Test: a key tool for monitoring the effectiveness of venom immunotherapy
-
The change in quality of life of adults with food allergy treated with oral immunotherapy
-
The effect of the sphenopalatine ganglion acupuncture on the clinical efficacy of cluster immunotherapy in patients with allergic rhinitis
-
The efficacy analysis and immunological changes after Alternaria alternata immunotherapy
-
The epicutaneous immunotherapy for peanut allergy: most recent results and perspectives
-
The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment
-
The journey to registration: challenges for allergen immunotherapy trials
-
The overall diet and environmental factors in oral immunotherapy
-
The safety of an optimal accelerated immunotherapy for allergic rhinitis in adolescent and adult patients in China (PERFECT study)
-
The successful switch of Hymenoptera venom immunotherapy (VIT) to a different manufacturer
-
The utility of basophil activation testing in honey bee venom allergy diagnosis and venom immunotherapy
-
Timing in oral immunotherapy : Early vs. Late introduction
-
Tolerance induction through oral immunotherapy
-
Trained innate immunity and immunotherapy
-
Treatment satisfaction and health literacy among patients undergoing allergen-specific immunotherapy -Data from a tertiary allergy centre
-
Tumor Necrosis Factor Receptor 2 (TNFR2) is crucial for the efficacy of Allergen-Specific Immunotherapy in a Pre-clinical Murine Model
-
Two-year Outcomes of Low-dose Oral Immunotherapy for Children with Severe Walnut Allergy
-
Understanding of mechanisms of food immunotherapy
-
Understanding the Patient: Their Preferences for Venom Immunotherapy
-
Updates in the clinical management of allergen immunotherapy
-
Using the AllergyVax app to increase adherence to allergen subcutaneous immunotherapy
-
Utility of basophil activation test (BAT) in evaluation of efficacy of venom immunotherapy determined by sting challenge: A systematic review
-
Validation of a novel serum-based basophil activation test (iBAT) to evaluate efficacy of a pivotal Phase III PQ Grass immunotherapy trial
-
Venom Allergen Immunotherapy in Children: Efficacy, Persistence of Efficacy and Impact on Quality of Life
-
Venom Allergen Immunotherapy in Children: Efficacy, Persistence of Efficacy and Impact on Quality of Life
-
Venom Immunotherapy in children and adolescents: safety and outcome in a study group from a third level Italian center
-
Venom immunotherapy in children – do we have an age limit ? (case report)
-
Venom immunotherapy in mastocytosis
-
When Immunotherapy Strikes Twice: IgE Hypersensitivity and HES as Dual Adverse Effects of Pembrolizumab
-
Where are we currently in sublingual immunotherapy for food allergy?
-
Why So Sensitive? Identifying New Allergic Sensitization in Patients On Subcutaneous Immunotherapy (SCIT)
-
Аllergen-specific immunotherapy in patients with allergic rhinitis
-
Сytokine profile in patients with allergic rhinitis during allergen-specific immunotherapy with added vitamin D
-
Сytokine profiles in patients with allergic rhinitis during allergen-specific immunotherapy with and without added vitamin D
-
“Picking the Harmony”: The Science Behind Immunotherapy Treatments
-
“Rhythm of Success”: Sustaining Benefits in Allergen Immunotherapy
-
“Tuning In”: Patient Profiles Orchestrating Optimized Response to Immunotherapy
-
Basophil activation test as a marker of desensitization in Very Low-Dose Multi-Nut Immunotherapy and Very Low-Dose Peanut Oral Immunotherapy
-
Effectiveness of allergy immunotherapy on asthma medication use and asthma exacerbations: Results from the Real world Evidence of aLlergy immunotherapY (RELY) study
-
Effectiveness of allergy immunotherapy on symptom-relieving medication use: Results from the Real world Evidence of aLlergy immunotherapY (RELY) study
-
Evaluation of Patients with Venom Immunotherapy Indication When Immunotherapy Preparation Could Not Be Obtained
-
Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units
Show more Sessions (390)Show Less-